PT-141 (Bremelanotide).
Melanocortin agonist acting centrally on sexual arousal pathways.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About PT-141 (Bremelanotide).
PT-141 (Bremelanotide) is a synthetic melanocortin-receptor agonist holding US FDA approval as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally — on arousal pathways in the hypothalamus — rather than peripherally on vasculature like PDE5 inhibitors.
Magistral compounding extends access to a broader population and allows physician-adjusted dosing protocols.
PT-141 is a cyclic heptapeptide agonist of melanocortin receptors MC4R and MC3R in the hypothalamus. Activation modulates dopaminergic signalling in the medial preoptic area, the central node of sexual arousal in both sexes.
Subcutaneous injection, typically 1.0–1.75 mg, taken 30–60 minutes before sexual activity. Maximum once per 24 hours, 8 times per month.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- 01Kingsberg SA, et al. — Bremelanotide for the treatment of hypoactive sexual desire disorder: two RCTs. Obstet Gynecol · 2019 · doi: 10.1097/AOG.0000000000003500
- INN / Name
- PT-141 (Bremelanotide)
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 10mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.